Skip to main
AVTX

Avalo Therapeutics (AVTX) Stock Forecast & Price Target

Avalo Therapeutics (AVTX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Avalo Therapeutics Inc. has experienced a notable pre-market increase of approximately 22%, reflecting growing investor confidence in its lead asset, AVTX-009, as the upcoming LOTUS data readout draws near and the potential for market expansion in the hidradenitis suppurativa (HS) treatment landscape becomes more apparent. The company's positioning of AVTX-009 as a potential best-in-class IL-1 blockade treatment, bolstered by its pharmacokinetic and pharmacodynamic advantages, suggests a strong competitive edge in the inflammatory disease market. With the current enterprise value estimated at $530 million, there is a favorable outlook for significant share price appreciation driven by anticipated positive Phase II results and broader market acceptance of innovative therapies.

Bears say

Avalo Therapeutics faces several significant challenges that contribute to a negative outlook on its stock. The company’s lead asset, AVTX-009, may struggle with efficacy limitations due to potential local inflammation from unblocked IL-1α, which could hinder the achievement of important clinical benchmarks, such as HiSCR response rates. Additionally, the competitive landscape is concerning, as noted failures of similar therapeutic candidates, along with risks of diluted ownership from potential financing needs due to slower-than-expected commercial uptake, further diminish the financial viability and growth prospects of the company.

Avalo Therapeutics (AVTX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Avalo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Avalo Therapeutics (AVTX) Forecast

Analysts have given Avalo Therapeutics (AVTX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Avalo Therapeutics (AVTX) has a Strong Buy consensus rating as of Mar 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Avalo Therapeutics (AVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.